DZ2376A1 - Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. - Google Patents

Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Info

Publication number
DZ2376A1
DZ2376A1 DZ970226A DZ970226A DZ2376A1 DZ 2376 A1 DZ2376 A1 DZ 2376A1 DZ 970226 A DZ970226 A DZ 970226A DZ 970226 A DZ970226 A DZ 970226A DZ 2376 A1 DZ2376 A1 DZ 2376A1
Authority
DZ
Algeria
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
sulfonamide derivatives
derivatives process
Prior art date
Application number
DZ970226A
Other languages
English (en)
Inventor
Steven Mark Bromidge
Francis David King
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626377.7A external-priority patent/GB9626377D0/en
Priority claimed from GBGB9700901.3A external-priority patent/GB9700901D0/en
Priority claimed from GBGB9722757.3A external-priority patent/GB9722757D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2376A1 publication Critical patent/DZ2376A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
DZ970226A 1996-12-19 1997-12-07 Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. DZ2376A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9626377.7A GB9626377D0 (en) 1996-12-19 1996-12-19 Novel compounds
GBGB9700901.3A GB9700901D0 (en) 1997-01-17 1997-01-17 Novel compounds
GBGB9722757.3A GB9722757D0 (en) 1997-10-27 1997-10-27 Novel compounds

Publications (1)

Publication Number Publication Date
DZ2376A1 true DZ2376A1 (fr) 2002-12-28

Family

ID=27268644

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970226A DZ2376A1 (fr) 1996-12-19 1997-12-07 Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Country Status (31)

Country Link
US (2) US6423717B1 (fr)
EP (1) EP0946539B1 (fr)
JP (1) JP2001506646A (fr)
KR (1) KR20000069554A (fr)
CN (1) CN1246116A (fr)
AP (1) AP1277A (fr)
AR (1) AR010795A1 (fr)
AT (1) ATE247099T1 (fr)
AU (1) AU729056B2 (fr)
BG (1) BG103530A (fr)
BR (1) BR9713734A (fr)
CA (1) CA2275492A1 (fr)
CZ (1) CZ220399A3 (fr)
DE (1) DE69724142T2 (fr)
DZ (1) DZ2376A1 (fr)
EA (1) EA002351B1 (fr)
ES (1) ES2203831T3 (fr)
HU (1) HUP0000658A3 (fr)
ID (1) ID22821A (fr)
IL (1) IL130297A0 (fr)
MA (1) MA24426A1 (fr)
NO (1) NO993003L (fr)
NZ (1) NZ335970A (fr)
OA (1) OA11066A (fr)
PE (1) PE46899A1 (fr)
PL (1) PL334337A1 (fr)
SK (1) SK80899A3 (fr)
TR (1) TR199901361T2 (fr)
TW (1) TW418205B (fr)
UY (1) UY24819A1 (fr)
WO (1) WO1998027081A1 (fr)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
HUP0003073A3 (en) * 1997-07-11 2002-10-28 Smithkline Beecham Plc Benzenesulfonamide derivatives, process for producing them and their use as medicines
WO1999038845A1 (fr) 1998-01-29 1999-08-05 Tularik Inc. MODULATEURS DU RECEPTEUR ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPARη)
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
AU2441801A (en) * 1999-12-21 2001-07-03 Smithkline Beecham Corporation Urotensin-ii receptor antagonists
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6399617B1 (en) 2000-07-21 2002-06-04 Biovitrum Ab Use
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0002739D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
US6818639B2 (en) 2000-07-21 2004-11-16 Biovitrum Ab Pharmaceutical combination formulation and method of treatment with the combination
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
WO2002022595A1 (fr) * 2000-09-18 2002-03-21 Toa Eiyo Ltd. Derives de benzothiophenesulfonamide substitue en n
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2002042293A1 (fr) * 2000-11-21 2002-05-30 Smithkline Beecham P.L.C. Derives d'isoquinoleine utiles pour le traitement de troubles du systeme nerveux central
US7132546B2 (en) 2000-12-22 2006-11-07 Ishihara Sangyo Kaisha, Ltd. Aniline derivatives or salts thereof and cytokine production inhibitors containing the same
AU2002256418A1 (en) * 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
WO2002089740A2 (fr) * 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
AR033879A1 (es) * 2001-05-07 2004-01-07 Smithkline Beecham Corp Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
EP1387679A4 (fr) * 2001-05-07 2004-08-11 Smithkline Beecham Corp Sulfonamides
US6849635B2 (en) * 2001-05-07 2005-02-01 Smithkline Beecham Corporation Sulfonamides
EP1385830A4 (fr) * 2001-05-07 2005-08-17 Smithkline Beecham Corp Sulfonamides
US6743796B2 (en) * 2001-05-07 2004-06-01 Wyeth Piperazinyl-isatins
GB0111186D0 (en) * 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
RS88803A (sr) * 2001-05-11 2007-02-05 Biovitrum Ab., Nova jedinjenja arilsulfonamida za lečenje gojaznosti, dijabetesa tipa ii i poremećaja cns
CN1329382C (zh) 2001-05-11 2007-08-01 比奥维特罗姆股份公司 治疗肥胖、ⅱ型糖尿病和cns－疾病的芳基磺酰胺化合物
PL367305A1 (en) 2001-06-07 2005-02-21 F.Hoffmann-La Roche Ag New indole derivatives with 5-ht6 receptor affinity
KR100889718B1 (ko) * 2001-06-11 2009-03-23 바이오비트럼 에이비(피유비엘) 치환 술폰아미드 화합물, ｃｎｓ 장애, 비만 및 ⅱ 형당뇨병 치료용 약제로서의 이들의 사용 방법
EP1401812B1 (fr) 2001-06-15 2006-06-28 F. Hoffmann-La Roche Ag Derives de 4-piperazinylindole a affinite avec les recepteurs 5-ht6
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
JP2005527463A (ja) * 2001-08-07 2005-09-15 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン
CA2456250A1 (fr) * 2001-08-10 2003-02-20 F. Hoffmann-La Roche Ag Derives d'arylsulfonyle avec affinite pour le recepteur 5-ht6
EP1433479B8 (fr) * 2001-09-05 2008-01-23 Eisai R&D Management Co., Ltd. Agents stimulant l'appetit et remedes contre l'anorexie
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
DE60232173D1 (de) * 2001-11-09 2009-06-10 Biovitrum Ab Publ Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
EA200400707A1 (ru) 2001-11-22 2004-10-28 Биовитрум Аб Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200400708A1 (ru) 2001-11-22 2004-10-28 Биовитрум Аб Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
JP2005516903A (ja) * 2001-11-30 2005-06-09 エフ．ホフマン−ラ　ロシュ　アーゲー 喘息の処置におけるｃｃｒ−３受容体拮抗物質として使用するためのピペラジン誘導体
EP1471912A1 (fr) * 2002-02-05 2004-11-03 Glaxo Group Limited Technique de stimulation de la croissance neuronale
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
US20050085461A1 (en) * 2002-02-13 2005-04-21 Cooper David G. Benzenesulfonamide derivatives
EP1487801B1 (fr) * 2002-02-13 2006-04-19 Glaxo Group Limited Derives de 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine presentant une affinite pour le recepteur 5-ht6, destines au traitement de troubles du snc
AU2003215558A1 (en) * 2002-02-13 2003-09-04 Glaxo Group Limited Benzenesulfonamide derivatives as antipsychotic agents
SI1497266T1 (sl) 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
US20040142948A1 (en) * 2002-05-07 2004-07-22 Dashyant Dhanak Sulfonamides
DE60303376T2 (de) * 2002-05-13 2006-11-16 F. Hoffmann-La Roche Ag Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
EP1897876A3 (fr) 2002-06-20 2009-03-18 Biovitrum AB (publ) Composés utiles pour le traitement de l'obésité, du diabète de type II et des troubles du système nerveux central
EA011581B1 (ru) * 2002-06-20 2009-04-28 Биовитрум Аб (Пабл) Конденсированные гетероциклические соединения, применимые для лечения ожирения и расстройств центральной нервной системы
DE60309498T2 (de) 2002-10-18 2007-08-30 F. Hoffmann-La Roche Ag 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
AU2003291262A1 (en) * 2002-11-06 2004-06-03 Smithkline Beecham Corporation Sulfonamides
WO2004043368A2 (fr) * 2002-11-06 2004-05-27 Smithkline Beecham Corporation Sulfonamides
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
US7153858B2 (en) 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
EP1597322A2 (fr) * 2003-02-13 2005-11-23 LANXESS Deutschland GmbH Complexes metalliques servant de composes photoabsorbants dans la couche d'information de supports de donnees optiques
CA2515780C (fr) * 2003-02-20 2012-12-11 Encysive Pharmaceuticals Inc. Antagonistes du recepteur de l'urotensine-ii de la phenylenediamine et antagonistes du ccr-9
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
WO2004087654A2 (fr) * 2003-03-31 2004-10-14 Janssen Pharmaceutica N.V. Inhibiteurs de phospholipase c a utiliser pour le traitement de troubles inflammatoires
US6946466B2 (en) * 2003-04-10 2005-09-20 Schering Ag Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
EP1558582B1 (fr) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Derives de diaryl et arylheteroaryl uree utilises en tant que modulateurs du recepteur de la serotonine 5-ht2a utiles pour la prophylaxie et le traitement de troubles associes a ce dernier
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
CA2545506A1 (fr) * 2003-12-19 2005-06-30 Biovitrum Ab Nouveaux derives de benzofurane, pouvant etre utilises dans la prophylaxie ou le traitement des affections associees au recepteur de 5-ht6
SE0303480D0 (sv) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
AU2005266448A1 (en) * 2004-07-28 2006-02-02 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
ES2348467T3 (es) * 2004-09-30 2010-12-07 F. Hoffmann-La Roche Ag Derivados y usos de la benzoxazina y la quinoxalina.
CA2583333C (fr) 2004-10-14 2013-05-14 Abbott Gmbh & Co. Kg Composes d'azabicycloheptyle destines au traitement des troubles reagissant a une modulation du recepteur de dopamine d<sb>3</sb>
EP2311802A1 (fr) * 2004-10-14 2011-04-20 Abbott GmbH & Co. KG Composes hétérocycliques convenant pour traiter des maladies sensibles une modulation du récepteur d3 de la dopamine
WO2006062481A1 (fr) * 2004-12-09 2006-06-15 Biovitrum Ab Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central
EP1676841A1 (fr) * 2004-12-30 2006-07-05 Esteve Laboratorios Dr. Esteve S.A. Composés substitués type sulphonamide d'indazole ou sulphonamide de 2,3-dihydroindole, leur préparation et leur utilisation comme médicaments
WO2006075808A1 (fr) * 2005-01-12 2006-07-20 Inje University Composition pharmaceutique comprenant un inhibiteur de p25/cdk5 permettant de prevenir ou de traiter une maladie neurodegenerative
EP2386554A1 (fr) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Composés actives sur le recepteur histamine H3
PT1919896E (pt) 2005-08-12 2010-02-26 Suven Life Sciences Ltd Derivados de aminoaril sulfonamida como ligandos funcionais de 5-ht6
WO2007020654A1 (fr) 2005-08-16 2007-02-22 Suven Life Sciences Procédé amélioré pour la préparation de losartane
EP1976495A2 (fr) * 2006-01-06 2008-10-08 Aarhus Universitet Composes agissant sur le transporteur de la serotonine
TW200808709A (en) 2006-03-31 2008-02-16 Glaxo Group Ltd Novel compounds
JP2009534355A (ja) 2006-04-19 2009-09-24 アボット ゲーエムベーハー ウント カンパニー カーゲー セロトニン５ｈｔ６受容体の調節に応答する障害を治療するために好適な複素環化合物
WO2007118899A1 (fr) * 2006-04-19 2007-10-25 Abbott Gmbh & Co. Kg Arylsulfones hétérocycliques pouvant être employés pour traiter des troubles qui répondent à la modulation du récepteur de la sérotonine 5ht6
JP2009537596A (ja) 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ６−（４−シクロプロピルピペリジン−１−イル）−２’−メチル−［３，４’］−ビピリジン及びその医薬としての使用
EP2079732B9 (fr) 2006-05-29 2012-03-21 High Point Pharmaceuticals, LLC 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyradine, ses sels et solvates et son utilisation comme antagoniste du recepteur d'histamin h3
US7906555B2 (en) 2006-10-26 2011-03-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance
MX2009006077A (es) 2007-01-08 2009-06-17 Suven Life Sciences Ltd Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.
CA2674644A1 (fr) * 2007-01-10 2008-07-17 F. Hoffmann-La Roche Ag Derives de sulfonamide en tant qu'inhibiteurs de la chymase
EP2155724A1 (fr) 2007-03-23 2010-02-24 Abbott GmbH & Co. KG Composés azétidine appropriés pour traiter des troubles qui répondent à la modulation du récepteur 5-ht<sb>6</sb>de la sérotonine
KR101162482B1 (ko) 2007-05-03 2012-07-03 수벤 라이프 사이언시스 리미티드 아미노알콕시 아릴술폰아미드 화합물 및 ５-ｈｔ６ 리간드로서의 그의 용도
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
EP2016943B1 (fr) * 2007-07-19 2011-02-23 Laboratorios del Dr. Esteve S.A. Composés de sulfamide de tetrahydro-quinoline substituée, leur préparation et utilisation en tant que médicament
DK2200980T3 (da) 2007-10-26 2011-11-21 Suven Life Sciences Ltd Aminoarylsulfonamidforbindelser og deres anvendelse som 5-HT6-ligander
PA8802201A1 (es) * 2007-11-02 2009-06-23 Abbott Gmbh & Co Kg Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
EP2254564A1 (fr) 2007-12-12 2010-12-01 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2297097A2 (fr) * 2008-06-11 2011-03-23 Irm Llc Composés et compositions utiles pour le traitement de la malaria
HRP20130721T1 (en) 2008-09-17 2013-09-30 Suven Life Sciences Limited Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
WO2010062321A1 (fr) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
KR101073703B1 (ko) 2009-04-07 2011-10-14 한국화학연구원 피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
UA107080C2 (uk) 2009-04-30 2014-11-25 Сполуки n-феніл(піперазиніл або гомопіперазиніл)бензолсульфонаміду або бензолсульфонілфеніл(піперазину або гомопіперазину), придатні для лікування захворювань, які реагують на модулювання рецептора 5-ht6 серотоніну
JP2012525356A (ja) * 2009-04-30 2012-10-22 アボット ゲーエムベーハー ウント カンパニー カーゲー セロトニン５−ｈｔ６受容体の調節に応答する障害を治療するのに適したベンゼンスルホンアニリド化合物
US8183237B2 (en) 2009-04-30 2012-05-22 Abbott Laboratories Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
AU2010340745B2 (en) 2010-01-05 2014-11-20 Suven Life Sciences Limited Sulfone compounds as 5-HT6 receptor ligands
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
WO2012059432A1 (fr) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Composés de type n-phényl-(homo)pipérazinyl-benzènesulfonyle ou benzènesulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6
WO2012059431A1 (fr) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Composés de type benzènesulfonyle ou sulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6 de la sérotonine
ES2413911B1 (es) * 2011-12-15 2014-05-14 Universidad De Zaragoza Agente inhibidor de la agregación del peptido beta amiloide.
AU2013237020B2 (en) 2012-03-20 2016-10-06 Adamed Sp. Z O.O. Sulphonamide derivatives of benzylamine for the treatment of CNS diseases
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ， インコーポレイテッド Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
KR20160034403A (ko) 2013-07-25 2016-03-29 유니버시테트 야기엘론스키 5-ht6 길항제로서의 피롤로퀴놀린 유도체, 및 이의 제조 방법 및 용도
CN105085436B (zh) 2014-04-19 2019-08-16 广东东阳光药业有限公司 磺酰胺类衍生物及其在药物上的应用
CN105367473B (zh) * 2014-08-12 2020-02-11 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
CN105367472B (zh) * 2014-08-12 2020-04-21 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
WO2017011767A2 (fr) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Dérivés d'arylhérétoaryl urée en tant que modulateurs du récepteur sérotoninergique 5-ht2a utiles pour la prophylaxie et le traitement d'hallucinations associées à une maladie neurodégénérative
CN108926565A (zh) * 2017-05-26 2018-12-04 中国科学院上海生命科学研究院 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
WO2019180176A1 (fr) 2018-03-21 2019-09-26 Spherium Biomed, S.L. Composition pour le traitement de la schizophrénie et/ou de la psychose
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
WO2020023910A1 (fr) 2018-07-26 2020-01-30 Tolero Pharmaceuticals, Inc. Procédés de traitement de maladies associées à l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destinés à être utilisés dans ceux-ci

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE81861C (fr)
NZ193654A (en) * 1979-05-16 1984-08-24 Wuelfing Johann A Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions
US4315014A (en) * 1980-09-24 1982-02-09 Warner-Lambert Company Antibacterial amide compounds and pharmaceutical composition containing the same
EP0076072B1 (fr) * 1981-09-24 1987-05-13 BEECHAM - WUELFING GmbH &amp; Co. KG Sulfonamides
CN85106905A (zh) * 1985-08-08 1987-02-04 Fmc公司 含有1-芳基-δ2-1，2，4，-三唑啉-5-酮类的除草剂及其制备方法
AU5175490A (en) * 1989-02-27 1990-09-26 Du Pont Merck Pharmaceutical Company, The Novel sulfonamides as radiosensitizers
JPH04330057A (ja) * 1991-05-01 1992-11-18 Hiroyoshi Hidaka アニリンアリールスルホン酸アミド類及び薬剤として許容され得るその酸付加塩
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE4206531A1 (de) * 1992-03-02 1993-09-09 Bayer Ag N-aryl-stickstoffheterocyclen
DE4303376A1 (de) * 1993-02-05 1994-08-11 Bayer Ag Substituierte Triazolinone
EP0716650B1 (fr) * 1993-09-03 1999-03-24 Smithkline Beecham Plc Nouveaux derives d'indole et d'indoline en tant qu'antagonistes du recepteur de 5ht1d
WO1995011243A1 (fr) * 1993-10-19 1995-04-27 Smithkline Beecham Plc Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
EP0733048A1 (fr) * 1993-12-07 1996-09-25 Smithkline Beecham Plc Biphenylylamides heterocycliques utilisables comme antagonistes du 5ht1d
US5756496A (en) * 1994-05-28 1998-05-26 Smithkline Beecham P.L.C. Amide derivatives having 5HT1D-antagonist activity
US5939451A (en) 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Also Published As

Publication number Publication date
AP1277A (en) 2004-05-05
TR199901361T2 (xx) 1999-08-23
KR20000069554A (ko) 2000-11-25
JP2001506646A (ja) 2001-05-22
NO993003D0 (no) 1999-06-18
AU6090498A (en) 1998-07-15
PL334337A1 (en) 2000-02-28
ES2203831T3 (es) 2004-04-16
PE46899A1 (es) 1999-06-24
AU729056B2 (en) 2001-01-25
ID22821A (id) 1999-12-09
DE69724142T2 (de) 2004-06-03
DE69724142D1 (de) 2003-09-18
TW418205B (en) 2001-01-11
EA199900561A1 (ru) 2000-02-28
AR010795A1 (es) 2000-07-12
MA24426A1 (fr) 1998-07-01
US6599904B2 (en) 2003-07-29
SK80899A3 (en) 2000-02-14
US6423717B1 (en) 2002-07-23
UY24819A1 (es) 2001-08-27
OA11066A (en) 2003-03-10
HUP0000658A3 (en) 2001-03-28
EP0946539B1 (fr) 2003-08-13
EP0946539A1 (fr) 1999-10-06
CZ220399A3 (cs) 1999-11-17
BG103530A (bg) 2000-01-31
US20030069233A1 (en) 2003-04-10
HUP0000658A2 (hu) 2001-02-28
IL130297A0 (en) 2000-06-01
ATE247099T1 (de) 2003-08-15
EA002351B1 (ru) 2002-04-25
CA2275492A1 (fr) 1998-06-25
AP9901556A0 (en) 1999-06-30
NO993003L (no) 1999-06-18
CN1246116A (zh) 2000-03-01
BR9713734A (pt) 2000-03-28
WO1998027081A1 (fr) 1998-06-25
NZ335970A (en) 2001-10-26

Similar Documents

Publication Publication Date Title
DZ2457A1 (fr) Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2407A1 (fr) Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2634A1 (fr) Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ2758A1 (fr) Dérivés bicycliques d0acide hydroxamique nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr) Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr) Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2621A1 (fr) AGonistes de prostaglandines nouveaux procédé pourleur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2666A1 (fr) Dérivés d&#39;acide hydroxamique compositions pharmaceutiques les contenant et procédé pour leur préparation.
MA26659A1 (fr) Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2198A1 (fr) Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26432A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2718136B1 (fr) Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant.
DZ3042A1 (fr) Dérivés d&#39;isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2870A1 (fr) Dérivés d&#39;acide hydroxypipécolate-hydroxamique nouveaux, procédé pour leur préparation et compositi ons pharmaceutiques les contenant.
DZ2227A1 (fr) Dérivés d&#39;indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2777A1 (fr) Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26558A1 (fr) Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
DZ2699A1 (fr) Dérivés d&#39;érythromycine nouveaux procédé et intermédiaires pour préparation et compositions pharmaceutiques les contenant.